ABSTRACT
No disponible
Subject(s)
Humans , Polycystic Kidney, Autosomal Recessive/diagnosis , Renal Insufficiency, Chronic/complications , Caroli Disease/diagnosis , Muscle Cramp/etiologySubject(s)
Kidney Failure, Chronic/etiology , Muscle Cramp/etiology , Polycystic Kidney, Autosomal Recessive/diagnosis , Adult , Caroli Disease/complications , Caroli Disease/diagnostic imaging , Cholangiopancreatography, Magnetic Resonance , Disease Progression , Female , Humans , Kidney Failure, Chronic/therapy , Peritoneal Dialysis , Polycystic Kidney, Autosomal Recessive/complications , Polycystic Kidney, Autosomal Recessive/diagnostic imaging , Ultrasonography , Weight LossABSTRACT
La amiloidosis secundaria o AA es una grave complicación de la enfermedad de Crohn (EC) evolucionada para la que no se dispone de un tratamiento eficaz. Presentamos un caso excepcional de un varón de 33 años afecto de insuficiencia renal moderada y proteinuria, que fue diagnosticado simultáneamente de nefropatía amiloide AA y de EC oligosintomática. Fue tratado con infliximab, 5 mg/kg/8 semanas durante 4 años, azatioprina 1-1,5 mg/kg/día (primer año) y un bloqueante del sistema renina-angiotensina-aldosterona, sin complicaciones. El tratamiento se siguió de una reducción de la proteinuria, mejoría de la función renal y de los parámetros inflamatorios a lo largo del tiempo. A propósito de este caso revisamos la literatura médica y concluimos que infliximab puede ser de utilidad para el tratamiento precoz de la amiloidosis secundaria en la EC (AU)
Secondary amyloidosis (AA) is a severe complication of progressed Crohn's disease (CD) for which no effective treatment exists. We present the exceptional case of a 33 year-old male with moderate renal failure and proteinuria, who was simultaneously diagnosed with AA amyloid nephropathy and oligosymptomatic CD. He was treated with infliximab at 5mg/kg/8 weeks for 4 years, azathioprine at 1-1.5mg/kg/day (first year) and renin-angiotensin-aldosterone system blockers, with no complications. Treatment caused a decrease in proteinuria, improved renal function, and improved inflammatory parameters over time. Inspired by this case, we performed a review of the medical literature and found that infliximab could be a useful tool in the early treatment of amyloidosis secondary to CD (AU)
Subject(s)
Humans , Male , Adult , Amyloidosis/drug therapy , Crohn Disease/complications , Antibodies, Monoclonal/pharmacokinetics , Proteinuria/complicationsABSTRACT
Secondary amyloidosis (AA) is a severe complication of progressed Crohn’s disease (CD) for which no effective treatment exists. We present the exceptional case of a 33 year-old male with moderate renal failure and proteinuria, who was simultaneously diagnosed with AA amyloid nephropathy and oligosymptomatic CD. He was treated with infliximab at 5mg/kg/8 weeks for 4 years, azathioprine at 1-1.5mg/kg/day (first year) and renin-angiotensin-aldosterone system blockers, with no complications. Treatment caused a decrease in proteinuria, improved renal function, and improved inflammatory parameters over time. Inspired by this case, we performed a review of the medical literature and found that infliximab could be a useful tool in the early treatment of amyloidosis secondary to CD.
